Millennium Pharmaceuticals Inc.

Cambridge, MA, United States

Millennium Pharmaceuticals Inc.

Cambridge, MA, United States

Time filter

Source Type

Patent
Millennium Pharmaceuticals Inc. and Massachusetts General Hospital | Date: 2016-06-03

Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.


Patent
Millennium Pharmaceuticals Inc. and Genentech | Date: 2017-05-17

Disclosed is a method for treating a human having a disease associated with leukocyte infiltration of mucosal tissues, comprising administering to said human an effective amount of a human or humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for 47 integrin. Preferably, no more than about 8 mg immunoglobulin or fragment per kg body weight are administered during a period of about one month.


Patent
Millennium Pharmaceuticals Inc. | Date: 2017-03-01

The invention relates to antibody molecules which bind pSYK, and methods for using the same for diagnosis, prognosis, to select patients for treatment with a SYK-targeted therapy, or evaluate the pharmacodynamic profile of a SYK-targeted therapy.


Patent
Millennium Pharmaceuticals Inc. | Date: 2017-02-22

This invention provides compounds of formula I and subsets thereof: wherein T, J, R, R4, Rq, o, RA, and RB and subsets thereof are as described in the specification. The compounds are inhibitors of NAMPT and are thus useful for treating cancer, inflammatory conditions, or T-cell mediated autoimmune disease.


Patent
Millennium Pharmaceuticals Inc. | Date: 2016-11-22

The present invention provides a method of treating nasopharyngeal cancer with a proteasome inhibitor of formula (7). The invention also provides a method of treating a patient with nasopharyngeal cancer based on elevated expression levels of NFkB, as measured by a H-score of the patients nasopharyngeal cancer tumor sample using a NFkB p65 IHC assay. The invention also provides a method of determining whether to treat a patient with the compound of formula (/) based on the level of NFkB p65 in the patients nasopharyngeal cancer tumor sample.


Patent
Millennium Pharmaceuticals Inc. and Sunesis Pharmaceuticals | Date: 2016-12-15

The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.


Patent
Millennium Pharmaceuticals Inc. | Date: 2017-05-31

Disclosed are chemical entities that inhibit ubiquitin-activating enzyme (UAE), each of which is a compound of Formula :^(Y), R^(Y1), R^(Y2) and R^(Y3) are defined herein; pharmaceutical compositions comprising the chemical entities; and methods of using the chemical entities. These chemical entities are useful for treating disorders, particularly cell proliferation disorders, including cancers.


The invention relates to a pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt thereof for the treatment of cancer and a process for its preparation. The invention also relates to administering the pharmaceutical composition to a patient according to an intermittent dosing regimen.


Patent
Millennium Pharmaceuticals Inc. | Date: 2017-04-17

Disclosed are chemical entities which are compounds of formula (I): or pharmaceutically acceptable salts thereof; wherein Y, R^(a), R^(a), R^(b), R^(c), X_(1), X_(2), X_(3), R^(d), Z_(1), and Z_(2 )have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.


Patent
Millennium Pharmaceuticals Inc. | Date: 2017-04-17

Disclosed are chemical entities that inhibit ubiquitin-activating enzyme (UAE), each of which is a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein Y is and W, Z, X^(Y), R^(Y1), R^(Y2 )and R^(Y3 )are defined herein; pharmaceutical compositions comprising the chemical entities; and methods of using the chemical entities. These chemical entities are useful for treating disorders, particularly cell proliferation disorders, including cancers.

Loading Millennium Pharmaceuticals Inc. collaborators
Loading Millennium Pharmaceuticals Inc. collaborators